Diverse Stocks in Expert’s Opinion: Advanced Micro Devices (NASDAQ:AMD), Accenture (NYSE:ACN)

Shares of Advanced Micro Devices, Inc. (NASDAQ:AMD) [Trend Analysis] runs in leading trade, it plunging -2.26% to traded at $10.37. The firm has price volatility of 4.34% for a week and 4.25% for a month. Its beta stands at 2.43 times. AMD (AMD) reported that for first-quarter 2017, based on a 13 week quarter, the company expects: revenue to decrease 11% sequentially, plus or minus 3%. The midpoint of revenue guidance would result in first-quarter revenue increasing approximately 18 percent from last year.

The company expects non-GAAP gross margin to be approximately 33%.For the full year 2017, based on 52 weeks, AMD expects: to grow annual revenue, expand gross margin and deliver non-GAAP net income; and THATIC JV-related licensing gain of approximately $50 million. Fourth-quarter revenue was $1.11 billion, up 15 percent year-over-year, primarily due to higher GPU sales. Loss per share was $0.06 compared to a loss per share of $0.13 a year ago. On a non-GAAP basis, loss per share was $0.01 compared to a loss per share of $0.10, prior year. Narrow down four to firm performance, its weekly performance was -0.67% and monthly performance was -10.53%. The stock price of AMD is moving down from its 20 days moving average with -3.06% and isolated positively from 50 days moving average with 1.35%.

Accenture plc (NYSE:ACN) [Trend Analysis] luring active investment momentum, shares a loss -0.66% to $113.87. Accenture (ACN) declared that it has agreed to acquire InvestTech Systems Consulting, a market leader in investment technology systems-integration and consulting services that supports many of the world’s largest asset managers and investment service providers.The acquisition will further expand Accenture’s capabilities to help global investment managers, institutional investors and asset servicers strengthen their competitiveness by staying in front of new and emerging digital innovations and technology paradigms. Terms of the transaction were not disclosed. The total volume of 2.34 Million shares held in the session was surprisingly higher than its average volume of 2514.83 shares. EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at 35.40%, and looking further price to next year’s EPS is 9.01%. While take a short look on price to sales ratio, that was 2.09 and price to earnings ratio of 16.85 attracting passive investors.

 

About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *